Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) have earned an average rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $206.71.
A number of brokerages recently commented on QNCX. Weiss Ratings downgraded shares of Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 26th. Leerink Partners assumed coverage on Quince Therapeutics in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $80.00 price target on the stock. Zacks Research raised Quince Therapeutics to a “hold” rating in a report on Wednesday, June 24th. Citigroup raised Quince Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday. Finally, Lifesci Capital upgraded Quince Therapeutics to a “strong-buy” rating in a report on Monday, June 29th.
View Our Latest Stock Report on Quince Therapeutics
Hedge Funds Weigh In On Quince Therapeutics
Quince Therapeutics Trading Up 3.3%
Shares of NASDAQ QNCX opened at $31.00 on Friday. The stock has a market cap of $31.62 million, a P/E ratio of -0.20 and a beta of 1.31. Quince Therapeutics has a 12-month low of $15.10 and a 12-month high of $909.98. The business’s fifty day simple moving average is $28.65 and its 200-day simple moving average is $24.02.
Quince Therapeutics (NASDAQ:QNCX – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($12.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($28.02) by $15.71.
About Quince Therapeutics
Quince Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for rare diseases. The company’s research centers on its erythrocyte-derived extracellular vesicle (EEV) platform, which uses patients’ red blood cells to encapsulate and deliver therapeutic compounds.
Quince’s lead investigational product is eDSP, formerly known as EryDex, an autologous red-blood-cell-based formulation of dexamethasone sodium phosphate being developed for ataxia-telangiectasia (A-T).
Featured Stories
- Five stocks we like better than Quince Therapeutics
- Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
- Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
